Humoral response and safety of the <scp>BNT162b2</scp> and <scp>mRNA</scp> ‐1273 <scp>COVID</scp> ‐19 vaccines in patients with haematological diseases treated with <scp>anti‐CD20</scp> antibodies: An observational study-Reference-Cited by-同舟云学术

Humoral response and safety of the BNT162b2 and mRNA ‐1273 COVID ‐19 vaccines in patients with haematological diseases treated with anti‐CD20 antibodies: An observational study

Published:2022-03-20 Issue:6 Volume:197 Page:709-713
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Nishikubo Masashi¹^ORCID,Shimomura Yoshimitsu¹²^ORCID,Maruoka Hayato³,Nasu Seiko³,Nishioka Tomomi⁴,Sakizono Kenji³,Mitsuyuki Satoshi¹,Kubo Tomoyo¹,Okada Naoki¹,Nakagawa Daishi¹,Kamijo Kimimori¹,Imoto Hiroharu¹^ORCID,Yamamoto Ryusuke¹,Nagai Yuya¹,Hiramoto Nobuhiro¹,Yoshioka Satoshi¹,Yonetani Noboru¹,Matsushita Akiko¹,Miyakoshi Chisato⁵,Doi Asako⁶,Ishikawa Takayuki¹

Affiliation:

1. Department of Hematology Kobe City Medical Center General Hospital Kobe Japan

2. Department of Environmental Medicine and Population Science, Graduate School of Medicine Osaka University Osaka Japan

3. Department of Clinical Laboratory Kobe City Medical Center General Hospital Kobe Japan

4. LSI Medience Laboratory Kobe City Medical Center General Hospital Kobe Japan

5. Department of Research Support, Center for Clinical Research and Innovation Kobe City Medical Center General Hospital Kobe Japan

6. Department of Infectious Diseases Kobe City Medical Center General Hospital Kobe Japan

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.18151

Reference10 articles.

1. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

2. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

3. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study

4. Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell–directed therapies

5. B Cell Reconstitution after Rituximab Treatment in Idiopathic Nephrotic Syndrome

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antigen-specific T helper cells and cytokine profiles predict intensity and longevity of cellular and humoral responses to SARS-CoV-2 booster vaccination;Frontiers in Immunology;2024-08-29

2. Ensitrelvir eradicates persistent SARS-CoV-2 infection in a follicular lymphoma patient treated with anti-CD20 antibodies;Journal of Infection and Chemotherapy;2024-02

3. Sequential cellular and humoral responses after repetitive COVID‐19 vaccination in patients treated with anti‐CD20 antibodies;British Journal of Haematology;2023-11-14

4. Humoral response and safety of the BNT162b2 and mRNA-1273 COVID-19 vaccines in allogeneic hematopoietic stem cell transplant recipients: An observational study;Journal of Infection and Chemotherapy;2023-03

5. Humoral and cellular responses after COVID-19 booster vaccination in patients recently treated with anti-CD20 antibodies;Blood Cancer Journal;2023-01-23